News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Calistoga Pharmaceuticals Announces Initiation of Phase 2 Trial of Delta-Isoform-Selective PI3 Kinase Inhibitor CAL-101 in Combination with Rituximab for the Treatment of Previously Untreated Elderly Patients with Chronic Lymphocytic Leukemia



10/19/2010 9:49:20 AM

SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 2 combination trial of CAL-101, the company’s oral, delta-selective PI3K inhibitor, plus rituximab (Rituxan®) in previously untreated, elderly patients with chronic lymphocytic leukemia (CLL).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES